Stock News

Analysts See $0.19 EPS for Enerflex Ltd. (EFX); Adamis Pharmaceuticals (ADMP) Shorts Lowered By 1.49%

Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) Logo

Analysts expect Enerflex Ltd. (TSE:EFX) to report $0.19 EPS on May, 3.They anticipate $0.09 EPS change or 32.14% from last quarter’s $0.28 EPS. T_EFX’s profit would be $16.83M giving it 20.47 P/E if the $0.19 EPS is correct. After having $0.30 EPS previously, Enerflex Ltd.’s analysts see -36.67% EPS growth. The stock decreased 0.64% or $0.1 during the last trading session, reaching $15.56. About 2,320 shares traded. Enerflex Ltd. (TSE:EFX) has 0.00% since April 23, 2017 and is . It has underperformed by 11.55% the S&P500.

Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) had a decrease of 1.49% in short interest. ADMP’s SI was 3.39 million shares in April as released by FINRA. Its down 1.49% from 3.45 million shares previously. With 496,400 avg volume, 7 days are for Adamis Pharmaceuticals Corporation (NASDAQ:ADMP)’s short sellers to cover ADMP’s short positions. The SI to Adamis Pharmaceuticals Corporation’s float is 11.61%. The stock increased 1.92% or $0.075 during the last trading session, reaching $3.975. About 82,419 shares traded. Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) has declined 20.00% since April 23, 2017 and is downtrending. It has underperformed by 31.55% the S&P500.

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company has market cap of $132.72 million. The companyÂ’s specialty pharmaceutical product candidates comprise Epinephrine Injection pre-filled syringe for use in the emergency treatment of acute allergic reactions, including anaphylaxis; dry powder inhaler products consisting of albuterol (APC-2000) and fluticasone (APC-4000) for the treatment of bronchospasm and asthma; and beclomethasone (APC-1000), a metered dose inhaler product for the asthma, as well as APC-1000 and APC-5000 for the treatment of asthma and chronic obstructive pulmonary disease. It currently has negative earnings. It also operates a 503B drug outsourcing facility that provides prescription compounded medications to patients, physician clinics, hospitals, surgery centers, and other clients in the United States.

Among 4 analysts covering Adamis Pharma (NASDAQ:ADMP), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Adamis Pharma had 10 analyst reports since December 1, 2015 according to SRatingsIntel. On Monday, June 12 the stock rating was maintained by Maxim Group with “Buy”. B. Riley & Co maintained Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) rating on Friday, March 23. B. Riley & Co has “Buy” rating and $6.25 target. The company was maintained on Monday, December 4 by Raymond James. The firm earned “Buy” rating on Monday, August 21 by Maxim Group. The stock has “Buy” rating by Maxim Group on Tuesday, December 1. Maxim Group maintained Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) on Thursday, July 21 with “Buy” rating. The stock of Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) earned “Buy” rating by Raymond James on Tuesday, September 12.

Among 6 analysts covering Enerflex (TSE:EFX), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Enerflex had 27 analyst reports since July 21, 2015 according to SRatingsIntel. Raymond James upgraded it to “Market Perform” rating and $15 target in Tuesday, August 11 report. The company was downgraded on Friday, August 7 by Scotia Capital. Scotia Capital downgraded the stock to “Outperform” rating in Friday, August 7 report. Raymond James maintained the shares of EFX in report on Friday, March 3 with “Outperform” rating. The company was maintained on Friday, August 7 by TD Securities. The firm earned “Sector Outperformer” rating on Wednesday, September 23 by IBC. The stock of Enerflex Ltd. (TSE:EFX) has “Buy” rating given on Monday, September 19 by TD Securities. The firm has “Outperform” rating given on Monday, August 10 by BMO Capital Markets.

Enerflex Ltd. supplies natural gas compression, gas and oil processing, refrigeration systems, and electric power equipment in Canada, the United States, and internationally. The company has market cap of $1.38 billion. The firm offers engineered systems, including engineering, design, fabrication, and assembly of standard and custom-designed compression, electric power, and processing solutions. It has a 14.15 P/E ratio. The Company’s compression solutions include engineering, designing, fabrication, and installation of natural gas compression packages, such as gasfuelled engines or electric motors, reciprocating or screw compressors, cooling fans, piping, and instrumentation and controls for applications in gas gathering compression, inlet, and residue compression in processing facilities, compression for gas storage, and pipeline compression.

Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) Ratings Chart

Leave a Reply

Your email address will not be published. Required fields are marked *